The study also aims to determine the effect of a strong enzyme (CYP3A4) inducer-rifampin- on
drug exposure of Glasdegib. This study will be conducted in healthy subjects given a single
dose of glasdegib in each period.
- Healthy female subjects of non-childbearing potential and/or male subjects who, at
the time of screening, are between the ages of 18 and 55 years, inclusive. Healthy
is defined as no clinically relevant abnormalities identified by a detailed medical
history, full physical examination, including blood pressure and pulse rate
measurement, 12-lead ECG or clinical laboratory tests.
- Female subjects of non childbearing potential must meet at least one of the following
1. Achieved postmenopausal status, defined as follows: cessation of regular menses
for at least 12 consecutive months with no alternative pathological or
physiological cause; AND have a serum follicle-stimulating hormone (FSH) level
confirming the post-menopausal state;
2. Have undergone a documented hysterectomy and/or bilateral oophorectomy;
3. Have medically confirmed ovarian failure.
- All other female subjects (including females with tubal ligations) will be considered
to be of childbearing potential.
- Body Mass Index (BMI) of 17.5 to 30.5 kg/m2; and a total body weight >50 kg (110
- Evidence of a personally signed and dated informed consent document indicating that
the subject has been informed of all pertinent aspects of the study.
- Subjects who are willing and able to comply with all scheduled visits, treatment
plan, laboratory tests, and other study procedures.
- A positive urine drug screen
- Screening supine 12 lead ECG demonstrating QTc >450 msec or a QRS interval >120 msec.
If QTc exceeds 450 msec, or QRS exceeds 120 msec, the ECG should be repeated two
more times and the average of the three QTc or QRS values should be used to determine
the subject's eligibility.
- Subjects with family history of myocardial infarction, congenital long QT syndrome,
torsades de pointes or clinically significant ventricular arrhythmias.
- Pregnant female subjects; breastfeeding female subjects; male subjects with partners
currently pregnant; male subjects able to father children who are unwilling or unable
to use two highly effective methods of contraception as outlined in this protocol for
the duration of the study and for at least 90 days after the last dose of
investigational product and, refrain from sperm donation for the duration of the
study and for at least 90 days after the last dose of investigational product.